Trials / Completed
CompletedNCT00710268
Study to Assess Safety & Tolerability of AZD2281 in Combination With Bevacizumab in Patients With Advanced Solid Tumours
A Phase I, Open Label, Dual Centre Study To Assess The Safety And Tolerability Of AZD2281 In Combination With Bevacizumab (Avastin®) In Patients With Advanced Solid Tumours
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 18 (actual)
- Sponsor
- AstraZeneca · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Phase I, open label, dual centre, dose finding study to evaluate the safety and tolerability of continuous twice daily oral dosing with AZD2281 when administered in combination with Bevacizumab 10mg/kg given every 2 weeks to patients with advanced solid tumours.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | AZD2281 | Oral Capsule, Dose Escalation 50, 100, 200, 400 mgContinuous twice daily dosing |
| DRUG | Bevacizumab | IV administration10 mg/kg every 14 days |
Timeline
- Start date
- 2008-06-01
- Primary completion
- 2009-03-01
- Completion
- 2009-11-01
- First posted
- 2008-07-04
- Last updated
- 2015-01-14
Locations
2 sites across 1 country: United Kingdom
Source: ClinicalTrials.gov record NCT00710268. Inclusion in this directory is not an endorsement.